Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study

Qing Wei(Chinese Academy of Sciences), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanru Xie(Lishui Central Hospital), Jing‐Jing Li(Shanghai Institute of Nutrition and Health), Zhiyuan Hu(Fujian Medical University), Cong Luo(Central South University), Zhe Han(University of Maryland, Baltimore), Lei Chen(Zhuzhou Central Hospital), Qi Xu(China Jiliang University), Wei Wu(Chinese Academy of Sciences), Weijun Chen(Zhejiang University), Chang Wang(Jilin University), Jiadong Chu(Chinese Academy of Sciences), Yanlian Yang(National Center for Nanoscience and Technology), Xiaoqing Xu(Zhejiang Chinese Medical University)
The Oncologist
February 16, 2024
10.1093/oncolo/oyae005
Cited by 10

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412